Suppr超能文献

鼠李糖乳杆菌 GG 对神经原性下尿路功能障碍患者的尿路症状负担的影响。

Effects of Intravesical Lactobacillus Rhamnosus GG on Urinary Symptom Burden in People with Neurogenic Lower Urinary Tract Dysfunction.

机构信息

Collaborative for Research on Outcomes and -Metrics, Silver Spring, MD, USA.

Departments of Neurology and Biostatistics, Bioinformatics & Biomathematics, Georgetown University Medical Center, Washington, DC, USA.

出版信息

PM R. 2021 Jul;13(7):695-706. doi: 10.1002/pmrj.12470. Epub 2020 Nov 10.

Abstract

OBJECTIVE

To test the effectiveness of intravesical Lactobacillus rhamnosus GG (LGG) to reduce the burden of urinary symptoms for individuals with spinal cord injury and disease (SCI/D) with neurogenic lower urinary tract dysfunction (NLUTD) who manage their bladders with intermittent catheterization (IC).

DESIGN

A three-phase study (6 months each in baseline, intervention, and washout). Participants self-managed following the Self-Management Protocol using Probiotics (SMP-Pro), completing the online Urinary Symptom Questionnaire for Neurogenic Bladder-IC version (USQNB-IC) weekly.

SETTING

Nationwide (United States).

PARTICIPANTS

Ninety-six adults and seven children with SCI/D.

INTERVENTIONS

In response to one or both of the SMP-Pro trigger urinary symptoms, "cloudier" or "foul smelling" urine, participants self-administered using a clean urinary catheter an LGG+ Normal Saline instillate once or twice in a 30-hour period.

MAIN OUTCOME MEASURES

Change in USQNB-IC burden was adjusted individually according to the previous phase for four symptom types. Adjusted changes in burden between the intervention and washout phases were analyzed using one-sample t-tests. Holm correction was applied for the four types of symptoms: A, clinically actionable; B1, bladder function; B2, urine quality; and C, other.

RESULTS

During the intervention phase, participants met SMP-Pro instillation criteria 3.83 times on average (range 1-20). An average of 5.6 doses of LGG were instilled. For those who instilled at least once, burdens of type A and B2 symptoms were significantly improved at washout (both adjusted P < .05).

CONCLUSIONS

Self-instilled LGG seemed to improve "clinically actionable" (A) and "urine quality" (B2) symptom burden. No changes were observed for those who did not instill. This first-in-human clinical trial supports ongoing research of intravesical LGG, and the SMP-Pro for urinary symptoms.

摘要

目的

测试膀胱内给予鼠李糖乳杆菌 GG(LGG)对伴有神经源性下尿路功能障碍(NLUTD)的脊髓损伤和疾病(SCI/D)患者减轻间歇性导尿(IC)管理下的尿路症状负担的效果。

设计

三阶段研究(基线、干预和洗脱期各 6 个月)。参与者按照益生菌自我管理方案(SMP-Pro)自我管理,每周在线填写神经源性膀胱-IC 版尿症状问卷(USQNB-IC)。

地点

全国范围(美国)。

参与者

96 名成人和 7 名儿童 SCI/D。

干预措施

针对 SMP-Pro 触发的一个或两个尿路症状(“浑浊”或“有异味”的尿液),参与者使用清洁的导尿管在 30 小时内自行给予 LGG+生理盐水灌洗一次或两次。

主要观察指标

根据前一阶段,针对四种症状类型,单独调整 USQNB-IC 负担的变化。使用单样本 t 检验分析干预和洗脱阶段之间的调整后负担变化。对四种症状类型(A,具有临床可操作性;B1,膀胱功能;B2,尿液质量;和 C,其他)应用 Holm 校正。

结果

在干预阶段,参与者平均符合 SMP-Pro 灌洗标准 3.83 次(范围 1-20)。平均给予 5.6 剂 LGG。对于至少灌洗一次的参与者,在洗脱时 A 型和 B2 型症状的负担显著改善(均调整 P<.05)。

结论

自行给予 LGG 似乎改善了“具有临床可操作性”(A)和“尿液质量”(B2)的症状负担。未观察到灌洗的参与者有任何变化。这是首次人体临床试验支持了膀胱内 LGG 和 SMP-Pro 治疗尿路症状的进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验